Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT278 vs NovoRapid and Humulin R U-500 in T2D Glucose Clamp Study
NCT05754424Phase 1Completed
- Sponsor
- Arecor Therapeutics
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT278 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Arecor Therapeutics. Primary endpoint: Area under the glucose infusion rate-time curve. Started Feb 2023; status: completed.
02
Drugs
AT278
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05754424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754424.